ASMB - Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting® | Benzinga
--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFN? pathway through a liver-focused approach to improve tolerability--
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.
"These data underscore our continued commitment to advancing innovative programs with the potential to change the treatment paradigm for patients impacted by serious viral diseases and highlight the promise of our preclinical IFNAR agonist program, which is in lead optimization," said William Delaney, PhD, chief scientific officer of Assembly Bio. "Additionally, the Phase 2 data reported for vebicorvir in combination with Nrtl and Arbutus Biopharma's AB-729 provide further insights that may inform future studies for the HBV and liver disease scientific community."
A poster presentation entitled "In Vitro and in Vivo Profiling of Orally Bioavailable Small Molecules Inhibiting Hepatitis B Virus by Mimicking Interferon Alpha" highlights preclinical data describing the inhibition of hepatitis B virus (HBV) and hepatitis C virus (HCV) in vitro through the activation of interferon (IFN) signaling by novel small molecule interferon-? (IFN?) receptor (IFNAR) agonists. The IFNAR agonists described in this poster closely mimic the biological activity of IFN? in vitro by stimulating cytokine secretion and inducing IFN-stimulated genes (ISG) following treatment of human cells. In addition, oral administration to preclinical species ...